Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 8 Results

Title
Intervention Indication Therapeutic Area Year Actions
Atezolizumab in addition to Carboplatin or Cisplatin and Pemetrexed for Stage IV non-squamous non-small cell lung cancer (NSCLC) Atezolizumab (Tecentriq; MPDL3280A) , Carboplatin (Paraplatin) , Cisplatin (Platinol) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2018 View  |  Download
Nintedanib in combination with Pemetrexed and Cisplatin for Unresectable Malignant Pleural Mesothelioma – first line Cisplatin (Platinol) , Nintedanib (Vargatef; Ofev; nintedanib esilate) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium) Malignant pleural mesothelioma (MPM) Lung and Respiratory Cancer 2018 View  |  Download
Osimertinib + pemetrexed + carboplatin +/ cisplatin as a first line treatment for non-small cell lung cancer with EGFR mutation Carboplatin (Paraplatin) , Cisplatin (Platinol) , Osimertinib (Tagrisso; AZD9291; osimertinib mesylate) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2023 View  |  Download
Pegargiminase in addition to pemetrexed and cisplatin for advanced malignant pleural mesothelioma – first line Cisplatin (Platinol) , Pegargiminase (ADI-PEG 20) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium) Malignant pleural mesothelioma (MPM) Lung and Respiratory Cancer 2018 View  |  Download
Pembrolizumab in addition to platinumpemetrexed chemotherapy for metastatic EGRF mutant non-squamous non-small-cell lung cancer – second line Pembrolizumab (Keytruda; MK-3475) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2020 View  |  Download
Pembrolizumab in combination with lenvatinib, platinum chemotherapy, and pemetrexed for non-small cell lung cancer Chemotherapy , Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2021 View  |  Download
Pembrolizumab in combination with pemetrexed and cisplatin for previously untreated advanced malignant pleural mesothelioma Cisplatin (Platinol) , Pembrolizumab (Keytruda; MK-3475) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium) Malignant pleural mesothelioma (MPM) Lung and Respiratory Cancer 2021 View  |  Download
Sintilimab in combination with pemetrexed and platinum chemotherapy for advanced or metastatic non-small cell lung cancer Carboplatin (Paraplatin) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium) , Sintilimab (IBI 308; IBI 380; Tyvyt) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2021 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications